[Pubmed] Mycobacterium abscessus Pulmonary Disease in a Myasthenia Gravis Patient: A Case Report
Posté : 15 juil. 2025 12:00
Respirol Case Rep. 2025 Jul 14;13(7):e70166. doi: 10.1002/rcr2.70166. eCollection 2025 Jul.
ABSTRACT
There is limited guidance on managing Mycobacterium abscessus pulmonary disease in Myasthenia Gravis patients. Macrolides and aminoglycosides form the backbone of M. abscessus pulmonary disease treatment but are avoided in Myasthenia Gravis patients due to the risk of precipitating myasthenic crisis. A 29-year-old female, with a history of anti-acetylcholine receptor antibody-positive Myasthenia Gravis and bronchiectasis, was diagnosed with M. abscessus pulmonary disease. She was commenced on a macrolide-based regime safely with close monitoring, pretreatment with intravenous immunoglobulin (1 g/kg),10 mg prednisolone, 500 mg rituximab and augmentation of the neuromuscular junction with pyridostigmine and 3,4-Diaminopyridine. She was safely discharged to the hospital in the home program and achieved clinical, radiological and microbiological response.
PMID:40661339 | PMC:PMC12256984 | DOI:10.1002/rcr2.70166
Source: https://pubmed.ncbi.nlm.nih.gov/4066133 ... t9+e462414